T1	corrected_chemical 52 72	miR-27a-3p inhibitor
T2	chemical 63 72	inhibitor
T3	disease_or_phenotypic_feature 91 107	epilepsy-induced
T4	corrected_disease_or_phenotypic_feature 91 129	epilepsy-induced inflammatory response
T5	missed_disease_or_phenotypic_feature 134 164	hippocampal neuronal apoptosis
T6	disease_or_phenotypic_feature 178 184	MAP2K4
T7	disease_or_phenotypic_feature 233 239	common
T8	disease_or_phenotypic_feature 247 256	infection
T9	disease_or_phenotypic_feature 274 285	candidiasis
T10	chemical 305 322	virulence factors
T11	chemical 428 439	regorafenib
T12	corrected_disease_or_phenotypic_feature 461 494	advanced hepatocellular carcinoma
T13	disease_or_phenotypic_feature 470 494	hepatocellular carcinoma
T14	chemical 501 510	sorafenib
T15	chemical 578 585	glucose
T16	disease_or_phenotypic_feature 617 632	type 1 diabetes
T17	chemical 688 695	insulin
T18	disease_or_phenotypic_feature 882 885	SSc
T19	chemical 882 885	SSc
T20	disease_or_phenotypic_feature 957 962	blood
T21	chemical 972 978	oxygen
T22	chemical 1081 1086	group
T23	disease_or_phenotypic_feature 1092 1096	PTSD
T24	chemical 1097 1102	group
T25	disease_or_phenotypic_feature 1249 1252	AML
T26	chemical 1283 1293	biomarkers
T27	disease_or_phenotypic_feature 1356 1359	get
T28	chemical 1440 1446	enzyme
T29	disease_or_phenotypic_feature 1476 1496	polyarteritis nodosa
T30	chemical 1502 1519	anti-phospholipid
T31	disease_or_phenotypic_feature 1574 1587	Brain Disease
T32	disease_or_phenotypic_feature 1591 1596	MPSII
T33	chemical 1640 1653	Nanoparticles
T34	disease_or_phenotypic_feature 1786 1789	DON
T35	chemical 1837 1847	biomarkers
T36	chemical 1852 1856	drug
T37	disease_or_phenotypic_feature 1922 1928	common
T38	chemical 1929 1938	mycotoxin
T39	corrected_chemical 2000 2021	flupentixol decanoate
T40	chemical 2012 2021	decanoate
T41	disease_or_phenotypic_feature 2042 2055	schizophrenia
T42	chemical 2299 2310	SP-EPN-MYCN
T43	chemical 2470 2479	molecular
T44	disease_or_phenotypic_feature 2487 2497	ependymoma
T45	chemical 2539 2552	tetracyclines
T46	chemical 2609 2628	anhydrotetracycline
T47	disease_or_phenotypic_feature 2775 2779	OTCs
T48	chemical 2807 2818	Tofacitinib
T49	chemical 2828 2842	small-molecule
T50	corrected_chemical 2828 2852	small-molecule inhibitor
T51	chemical 2843 2852	inhibitor
T52	disease_or_phenotypic_feature 2901 2921	rheumatoid arthritis
T53	corrected_chemical 2944 2976	dipeptidyl peptidase-4 inhibitor
T54	chemical 2967 2976	inhibitor
T55	chemical 2977 2988	saxagliptin
T56	missed_chemical 3006 3029	antihyperglycemic agent
T57	disease_or_phenotypic_feature 3047 3062	type 2 diabetes
T58	disease_or_phenotypic_feature 3269 3276	anxiety
T59	disease_or_phenotypic_feature 3277 3286	disease-7
T60	disease_or_phenotypic_feature 3300 3307	Anxiety
T61	chemical 3399 3414	NEO-personality
T62	chemical 3426 3433	NEO-PI)
T63	chemical 3560 3569	molecular
T64	disease_or_phenotypic_feature 3584 3587	CHM
T65	chemical 3727 3734	protein
T66	disease_or_phenotypic_feature 3807 3822	type 2 diabetes
T67	disease_or_phenotypic_feature 3863 3876	liver disease
R1	treats Arg1:T1 Arg2:T5
R2	treats Arg1:T1 Arg2:T4
R3	treats Arg1:T56 Arg2:T57
R4	treats Arg1:T53 Arg2:T57
R5	treats Arg1:T14 Arg2:T13
R6	treats Arg1:T14 Arg2:T12
R7	treats Arg1:T55 Arg2:T57
R8	treats Arg1:T17 Arg2:T16
R9	treats Arg1:T39 Arg2:T41
R10	treats Arg1:T48 Arg2:T52
R11	treats Arg1:T11 Arg2:T12
R12	treats Arg1:T50 Arg2:T52
